Clinical Trials
3
Active:0
Completed:1
Trial Phases
2 Phases
Phase 1:1
Phase 3:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 3
2 (66.7%)Phase 1
1 (33.3%)Study Evaluating PEG-G-CSF Injectionin Preventing Neutropenia After Chemotherapy
Phase 3
Not yet recruiting
- Conditions
- Neutropenia, Chemotherapy-Induced FebrileBreast Neoplasm Female
- Interventions
- Drug: PEG-G-CSF injection (Kexing Biopharmaceutical Co., Ltd.)Drug: PEG-G-CSF injection (Neulasta®，Amgen Europe B.V.)
- First Posted Date
- 2024-12-02
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Kexing Biopharm Co., Ltd.
- Target Recruit Count
- 250
- Registration Number
- NCT06711523
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
Human Interferon α1b Inhalation Solution Against Respiratory Syncytial Virus in Children With Lower Respiratory Tract Infections
Phase 3
Recruiting
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Drug: Human interferon α1b Inhalation SolutionDrug: Inhalation Solution Placebo
- First Posted Date
- 2024-04-12
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- Kexing Biopharm Co., Ltd.
- Target Recruit Count
- 322
- Registration Number
- NCT06363370
- Locations
- 🇨🇳
Children's Hospital, Capital Institute of Pediatrics, Beijing, Beijing, China
A Phase I Study in Healthy Participants
Phase 1
Completed
- Conditions
- Healthy Participants
- Interventions
- Drug: Human interferon alfa 1b inhalation solution placeboDrug: Human interferon alfa 1b inhalation solution
- First Posted Date
- 2024-02-26
- Last Posted Date
- 2024-05-01
- Lead Sponsor
- Kexing Biopharm Co., Ltd.
- Target Recruit Count
- 35
- Registration Number
- NCT06277167
- Locations
- 🇨🇳
The Third Hospital of Changsha, Changsha, China
News
No news found